Elevated Intraocular Pressure

DrugDrug NameDrug Description
DB00195BetaxololA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
DB00484BrimonidineBrimonidine is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. A topical gel formulation, marketed under the name Mirvaso, was FDA approved on August 2013 for the treatment of rosacea.
DB01194BrinzolamideBrinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DB01144DiclofenamideA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
DB00449DipivefrinDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
DB00869DorzolamideDorzolamide is a carbonic anhydrase (CA) inhibitor. It is used in ophthalmic solutions (Trusopt) to lower intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
DB01085PilocarpineA slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
DB08819TafluprostA prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012.
DB00373TimololA beta-adrenergic antagonist similar in action to propranolol. The levo-isomer is the more active. Timolol has been proposed as an antihypertensive, antiarrhythmic, antiangina, and antiglaucoma agent. It is also used in the treatment of migraine disorders and tremor.
DB00287TravoprostTravoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
DrugDrug NameTargetType
DB00195BetaxololBeta-1 adrenergic receptortarget
DB00195BetaxololBeta-2 adrenergic receptortarget
DB00195BetaxololCytochrome P450 1A2enzyme
DB00195BetaxololCytochrome P450 2D6enzyme
DB00484BrimonidineAlpha-2A adrenergic receptortarget
DB00484BrimonidineAlpha-2B adrenergic receptortarget
DB00484BrimonidineAlpha-2C adrenergic receptortarget
DB00484BrimonidineAldehyde oxidaseenzyme
DB01194BrinzolamideCarbonic anhydrase 1target
DB01194BrinzolamideCarbonic anhydrase 2target
DB01194BrinzolamideCytochrome P450 3A4enzyme
DB01194BrinzolamideCarbonic anhydrase 5A, mitochondrialtarget
DB01194BrinzolamideCarbonic anhydrase 4target
DB01194BrinzolamideCarbonic anhydrase 3target
DB01144DiclofenamideCarbonic anhydrase 1target
DB01144DiclofenamideCarbonic anhydrase 4target
DB01144DiclofenamideCarbonic anhydrase 2target
DB01144DiclofenamideCarbonic anhydrase 7target
DB01144DiclofenamideCarbonic anhydrase 3target
DB00449DipivefrinAlpha-2A adrenergic receptortarget
DB00449DipivefrinBeta-2 adrenergic receptortarget
DB00449DipivefrinAlpha-1A adrenergic receptortarget
DB00869DorzolamideCarbonic anhydrase 2target
DB00869DorzolamideCarbonic anhydrase 1target
DB00869DorzolamideCarbonic anhydrase 4target
DB00869DorzolamideCytochrome P450 2C9enzyme
DB00869DorzolamideCytochrome P450 3A4enzyme
DB00869DorzolamideCarbonic anhydrase 3target
DB01085PilocarpineMuscarinic acetylcholine receptor M1target
DB01085PilocarpineMuscarinic acetylcholine receptor M2target
DB01085PilocarpineCytochrome P450 2A6enzyme
DB01085PilocarpineMuscarinic acetylcholine receptor M3target
DB01085PilocarpineCytochrome P450 2E1enzyme
DB01085PilocarpineCytochrome P450 3A4enzyme
DB01085PilocarpineMuscarinic acetylcholine receptor M4target
DB08819TafluprostProstaglandin F2-alpha receptortarget
DB08819TafluprostProstaglandin G/H synthase 2enzyme
DB00373TimololBeta-1 adrenergic receptortarget
DB00373TimololBeta-2 adrenergic receptortarget
DB00373TimololCytochrome P450 2D6enzyme
DB00373TimololMultidrug resistance protein 1transporter
DB00373TimololCytochrome P450 2C19enzyme
DB00287TravoprostProstaglandin F2-alpha receptortarget
DrugDrug NamePhaseStatusCount